
Join experts Drs. Amy Paller and Peter Lio at an educational symposium as they investigate atopic dermatitis as a risk factor for the development of food allergies. The speakers will also discuss the benefits of early intervention in pediatric atopic dermatitis and the potential for disease modification.
Dr Donna Culton walks through the pathophysiology of type 2 inflammation in inflammatory skin diseases, using bullous pemphigoid as an example. Drs Eichenfield, Elmariah, and Hawkes join to discuss the role of type 2 inflammation across atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria, respectively.

Highlights from the ADVENT symposium at the Inflammatory Skin Disease Summit (ISDS) 2023 exploring the role of type 2 inflammation in atopic dermatitis.
An infographic to explore the the key roles of CCL17 (TARC) in atopic dermatitis.

Learn about type 2 inflammation as a driver of neurosensitization and chronic itch in atopic dermatitis with this educational tool.

This podcast episode looks at the epidemiology, clinical presentation and classification of atopic dermatitis of the hand and feet and the impact it has on patients' quality of life.

An interactive tool used to explore the global burden of atopic dermatitis in children and adolescents.

Professor Lisa Beck explores the chronic and persistent burden of atopic dermatitis (AD) as well as the concept of early intervention in patients with AD.

This podcast episode discusses best practices for the diagnosis of atopic dermatitis of the hands and feet
This page presents educational material, infographics, and video highlights from our recent ADVENT symposia, including the 2025 World Congress of Pediatric Dermatology (WCPD) in Buenos Aires, Argentina, exploring the pathophysiology of type 2 inflammation and atopic dermatitis, the burden of disease leading to cumulative life course impairment (CLCI), and the risk of the atopic march in pediatric patients with atopic dermatitis.

Watch this short video to learn how type 2 inflammation, skin barrier dysfunction, and neurosensitization contribute to chronic itch and the itch-scratch cycle in atopic dermatitis
The underlying pathophysiology of atopic dermatitis (AD) is driven by dysregulation of type 2 immunity that contributes to skin barrier dysfunction. AD typically develops very early in life and children with AD often develop other atopic conditions such as food allergy, asthma, and allergic rhinitis in a progression called the atopic march. Early treatment may help reduce the atopic march and other comorbidities to lessen the lifetime burden created by these diseases. There may even be a window of opportunity for disease modification.